Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by bfwon Feb 03, 2019 4:23pm
98 Views
Post# 29312456

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:SeekingAlpha.com report now available to all

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:SeekingAlpha.com report now available to allIt could take a few a few months to get all the data out.

We are going through this with RVX right now. They will be announcing the end of dosing soon and then need to adjudicate all events and do safety follow up visits with the patients. They then do a data lock and eventually report top line results a few months later.

In TH’s case, they may would have been analyzing results while possibly waiting for follow up visits (after biopsy, imaging and drug washout).

It’s possible that all dosing ended in November and data has been locked for some time.

bfw




palinc2000 wrote: Nash was first included in the Presentation on or around Nov 28 th...If the trigger for inclusion was that they had been made aware of positive results then  I would think that the results would be oiut by now.
Analysis of the data might take some time but nowhere close to 2 months ....

All I want to point out is that the inclusion in the Corporate Presentation is a neutral event...Not positive nor negative just part of normal disclosure by a public company


Bullboard Posts